Turn Therapeutics (NASDAQ:TTRX) Cut to “Sell” at Wall Street Zen

Wall Street Zen cut shares of Turn Therapeutics (NASDAQ:TTRX) from a hold rating to a sell rating in a research note issued to investors on Saturday,Wall Street Zen reports.

Several other analysts have also recently weighed in on TTRX. Zacks Research raised shares of Turn Therapeutics to a “hold” rating in a research note on Tuesday, July 21st. LADENBURG THALM/SH SH raised shares of Turn Therapeutics to a “strong-buy” rating in a research report on Monday, July 20th. Finally, Weiss Ratings lowered Turn Therapeutics from a “sell (d-)” rating to a “sell (e+)” rating in a research report on Tuesday, August 18th. One equities research analyst has rated the stock with a Strong Buy rating, one has assigned a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat, the company presently has an average rating of “Moderate Buy” and an average price target of $8.00.

Turn Therapeutics Price Performance

NASDAQ TTRX opened at $9.80 on Friday. Turn Therapeutics has a 52 week low of $2.57 and a 52 week high of $26.50. The company has a quick ratio of 1.19, a current ratio of 1.19 and a debt-to-equity ratio of 8.83. The business’s fifty day simple moving average is $9.23 and its 200-day simple moving average is $6.01. The firm has a market cap of $291.94 million and a PE ratio of -33.79.

Turn Therapeutics (NASDAQ:TTRX) last announced its quarterly earnings results on Wednesday, August 12th. The company reported ($0.20) earnings per share for the quarter. As a group, equities analysts anticipate that Turn Therapeutics will post -0.4 earnings per share for the current year.

Institutional Inflows and Outflows

Hedge funds have recently bought and sold shares of the stock. Jefferies Financial Group Inc. acquired a new stake in shares of Turn Therapeutics during the second quarter valued at about $119,000. Bank of America Corp DE purchased a new position in shares of Turn Therapeutics during the 2nd quarter worth approximately $103,000. Ieq Capital LLC purchased a new position in shares of Turn Therapeutics during the 2nd quarter worth approximately $1,660,000. BlackRock Inc. acquired a new stake in Turn Therapeutics in the 2nd quarter valued at approximately $282,000. Finally, Bridgewater Advisors Inc. purchased a new stake in Turn Therapeutics in the second quarter valued at approximately $242,000.

Turn Therapeutics Company Profile

We are a pharmaceutical and medical device development company built around a proprietary platform technology designed to enhance drug performance. Our patented mixing process — commercially referred to as PermaFusion™ (“PermaFusion”) — enables stable suspension of polar, water-soluble active pharmaceutical ingredients (“APIs”) in oil-based carriers without the use of emulsifiers. This innovation reduces the quantity of required API inclusion by improving its bioavailability. Reduced API load reduces the likelihood of adverse events.